4 January 2017

Holding(s) in Company

RNS Number : 3219T
Verona Pharma PLC
04 January 2017
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached:
ii

Verona Pharma plc   

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to the
notification obligation:
iii

Wales Life Sciences Investment Fund LP

4. Full name of shareholder(s)
 (if different from 3.):iv

5. Date of the transaction and date on
which the threshold is crossed or
reached:
v

3 January 2017

6. Date on which issuer notified:

3 January 2017

7. Threshold(s) that is/are crossed or
reached:
vi, vii

4.1%

         

 

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of
shares


if possible using
the ISIN CODE

Situation previous
to the triggering
transaction

Resulting situation after the triggering transaction

Number
of
Shares

Number
of
Voting
Rights

Number
of shares

Number of voting
rights

% of  voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary

207,500,000

207,500,000

105,500,000

105,500,000

4.1%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial
instrument

Expiration
date
xiii

Exercise/
Conversion Period
xiv

Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.

% of voting
rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial
instrument

Exercise price

Expiration date xvii

Exercise/
Conversion period
xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

105,500,000

4.1%

                                 

 

 

9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable:
xxi

Wales Life Sciences Investment Fund LP, as a stand-alone entity, previously held 8.1% of voting rights of Verona Pharma plc. After this disposal it holds 4.1%

 

The Wales Life Sciences Investment Fund LP is managed by Arthurian Life Sciences Ltd.

Arix Bioscience plc is the parent of Arthurian Life Sciences Ltd.

Arix Bioscience plc separately holds 2.5% of the voting rights which remain unchanged.

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold
voting rights:


13. Additional information:


 

14. Contact name:

Shafia Zahoor

15. Contact telephone number:

020-7290-1057

     

 

 

Note: Annex should only be submitted to the FCA not the issuer

Annex: Notification of major interests in share

A: Identity of the persons or legal entity subject to the notification obligation

Full name

(including legal form of legal entities)

 

Wales Life Sciences Investment Fund LP

Contact address

(registered office for legal entities)

 

20 Berkeley Square, London W1J 6EQ

Phone number & email

 

020-7290-1057

Other useful information

(at least legal representative for legal persons)

 

B: Identity of the notifier, if applicable

Full name

 

Shafia Zahoor

Contact address

 

20 Berkeley Square, London W1J 6EQ

Phone number & email

 

020-7290-1057

shafia@arixbioscience.com

Other useful information

(e.g. functional relationship with the person or legal entity subject to the notification obligation)

C: Additional information

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUGUWGGUPMGUC

For further information please contact:

 

Verona Pharma plc
Jan-Anders Karlsson, CEO
Tel: +44 (0)20 3283 4200
info@veronapharma.com

N+1 Singer (Nominated Adviser and UK Broker)
Aubrey Powell / James White
Tel: +44 (0)20 7496 3000

 

 

FTI Consulting
Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins
Tel: +44 (0)20 3727 1000
veronapharma@fticonsulting.com

ICR, Inc. (US Media and Investor enquiries)
James Heins
Tel: +1 203-682-8251
James.Heins@icrinc.com

Stephanie Carrington
Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com


Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us